TY - JOUR
T1 - High levels of Epstein‐Barr virus in the oropharynx
T2 - A predictor of disease progression in human immunodeficiency virus infection
AU - Diaz‐Mitoma, Francisco
AU - Ruiz, Alejandra
AU - Flowerdew, Gordon
AU - Houston, Stanley
AU - Romanowski, Barbara
AU - Kovithavongs, T.
AU - Preiksaitis, Jutta
AU - Tyrrell, D. Lorne
PY - 1990/6
Y1 - 1990/6
N2 - The role of Epstein‐Barr virus (EBV) on the progression of human immunodeficiency virus (HIV) infection is not well defined. The objective of this prospective study was to determine the prevalence of EBV excretion and the rol that EBV might have on HIV disease progression. Fifty‐two homosexual males were studied, all of whom had positive EBV serology. Twenty‐four of the 27 HIV‐seropositive and 14 of the 25 HIV‐seronegative subjects had detectable levels of EBV DNA in oropharyngeal cells. In addition to a greater prevalence of detectable EBV, the level of excretion was higher among HIV‐seropositives than among HIV‐seronegatives, and higher among group III than among group II HIV‐seropositive men. These results are consistent with earlier studies showing a relationship between immunosuppression and EBV reactivation. The EBV excretion levels in a control group of 52 age‐matched heterosexual males were substantially lower than those found in the homosexual group. In a proportional hazards regression analysis EBV excretion was found to be the best single predictor of progression of HIV infection (P<0.001). HIV p24 core antigenemia (P=0.048) and low EBNA (P=0.024) were significant predictors independent of EBV excretion. Whether EV directly accelerates the time to progression or is merely a marker of underlying subclinical immunosuppression remains an open question.
AB - The role of Epstein‐Barr virus (EBV) on the progression of human immunodeficiency virus (HIV) infection is not well defined. The objective of this prospective study was to determine the prevalence of EBV excretion and the rol that EBV might have on HIV disease progression. Fifty‐two homosexual males were studied, all of whom had positive EBV serology. Twenty‐four of the 27 HIV‐seropositive and 14 of the 25 HIV‐seronegative subjects had detectable levels of EBV DNA in oropharyngeal cells. In addition to a greater prevalence of detectable EBV, the level of excretion was higher among HIV‐seropositives than among HIV‐seronegatives, and higher among group III than among group II HIV‐seropositive men. These results are consistent with earlier studies showing a relationship between immunosuppression and EBV reactivation. The EBV excretion levels in a control group of 52 age‐matched heterosexual males were substantially lower than those found in the homosexual group. In a proportional hazards regression analysis EBV excretion was found to be the best single predictor of progression of HIV infection (P<0.001). HIV p24 core antigenemia (P=0.048) and low EBNA (P=0.024) were significant predictors independent of EBV excretion. Whether EV directly accelerates the time to progression or is merely a marker of underlying subclinical immunosuppression remains an open question.
UR - http://www.scopus.com/inward/record.url?scp=0025366052&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025366052&partnerID=8YFLogxK
U2 - 10.1002/jmv.1890310202
DO - 10.1002/jmv.1890310202
M3 - Article
C2 - 2167351
AN - SCOPUS:0025366052
SN - 0146-6615
VL - 31
SP - 69
EP - 75
JO - Journal of Medical Virology
JF - Journal of Medical Virology
IS - 2
ER -